Business Model Breakdown
How Sarepta Therapeutics Inc Makes Money
SRPT
Market Cap
$1.9B
Annual Revenue
$731M
Profit Margin
3.0%
Employees
1,372
The Short Version
Sarepta Therapeutics is a biopharmaceutical company specializing in the development and commercialization of precision genetic medicines, primarily focusing on rare diseases like Duchenne muscular dystrophy (DMD). The company generates revenue through the sale of its approved therapies, such as the gene therapy Elevidys and RNA-targeted exon-skipping drugs, to patients through healthcare providers. Additionally, they engage in strategic collaborations with other pharmaceutical companies, granting regional development and commercialization rights in exchange for upfront payments, milestones, and royalties. Their core strategy involves extensive research and development to bring innovative, often first-in-class, therapies through rigorous clinical trials and regulatory approval processes to address high unmet medical needs in niche patient populations.
Where the Revenue Comes From
Product Sales (e.g., Elevidys, Exondys 51, Vyondys 53, Amondys 45)
Collaboration and Contract Manufacturing Revenue (e.g., Roche option, Japan milestone)
Who buys: Patients diagnosed with rare genetic diseases, predominantly Duchenne muscular dystrophy, and the healthcare providers who prescribe and administer these specialized, often high-cost, treatments.
Why It Works (Competitive Advantages)
- ✔First-mover advantage in the DMD gene therapy market with Elevidys.
- ✔Proprietary phosphorodiamidate morpholino oligomer (PMO) technology platform for RNA-targeted therapies.
- ✔Diversifying pipeline with promising assets in other genetic diseases (e.g., siRNA programs).
Economic Moat: Narrow (Intangible Assets/IP (Strong patent protection for its gene therapies and PMO platform), Switching Costs (For patients effectively treated by their therapies, although new, superior treatments can reduce this), First-Mover Advantage (Elevidys' initial entry into the DMD gene therapy market))
What Our Analysis Says
DVR Score as of June 1, 2026
Score Change Explanation: The previous analysis (2026-04-05) highlighted "persistent commercial execution issues for Elevidys, reflected in Q4 2025's wider-than-expected loss and reduced 2026 revenue guidance." The Q1 2026 earnings, reported on May 6, 2026, represent a material positive change. Sarepta reported a significant swing to GAAP operating income of $358.4 million and GAAP net income of $331.0 million, compared to substantial losses a year prior. Furthermore, EPS of $2.88 significantly beat expectations. This strong return to profitability and EPS beat directly addresses a major concern from the prior analysis, justifying a material increase in the score. While 2026 revenue guidance ($1.2B-$1.4B) remains below 2025's actuals, indicating a revenue contraction for the year, the operational efficiency and profitability turnaround are highly positive signals. Sarepta maintains a first-mover advantage in DMD gene therapy, with a promising pipeline and strategic collaborations, offering significant long-term growth potential if commercial execution and regulatory hurdles are successfully navigated.